Zentalis Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€22.91M - Cost of goods sold
€406.86K - Gross profit
€22.51M - SG&A expenses
€62.81M - R&D expenses
€106.32M - EBITDA
-€152.19M - D&A
€680.66K - EBIT
-€156.06M - Interest expenses
€0.00 - EBT
-€139.04M - Tax expenses
-€197.88K - Net income
-€138.85M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€33.72M - Changes in working capital
-€11.26M - Operating cash flow
-€128.87M - Capex
€0.00 - Other investing cash flow
€59.71K - Net investing cash flow
€129.12M - Total cash dividends paid
€0.00 - Issuance of common stock
€239.68K - Debt repayment
€0.00 - Other financing cash flow
€0.00 - Net financing cash flow
€239.68K - Foreign exchange effects
€0.00 - Net change in cash
€485.33K - Cash at end of period
€34.31M - Free cash flow
-€128.87M
Balance sheet
- Cash and cash equivalents
€32.07M - Cash and short-term investments
€258.81M - Total receivables
€2.09M - Inventory
€0.00 - Other current assets
€4.87M - Total current assets
€265.78M - Property, plant & equipment
€29.22M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€4.99M - Total non-current assets
€34.21M - Total assets
€299.99M - Accounts payable
€3.17M - Short-term debt
€3.09M - Other current liabilities
€27.02M - Total current liabilities
€33.28M - Long-term debt
€32.15M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€426.48K - Total non-current liabilities
€32.57M - Total liabilities
€65.86M - Common stock
€61.41K - Retained earnings
-€963.45M - Other equity
€50.32K - Total equity
€234.13M - Total liabilities and shareholders' equity
€299.99M
Company information
- Market capitalization
€72.42M - Employees
166 - Enterprise Value
€114.00M
Company ratios
- Gross margin
-
98.2% Much better than peer group: -246.5% - EBITDA margin
-
-664.2% Much better than peer group: -3,148.5% - EBIT margin
-
-681.0% Much better than peer group: -3,252.2% - EBT margin
-
-606.8% Much better than peer group: -3,020.7% - Net margin
-
-605.9% Much better than peer group: -3,009.5% - ROE
-
-59.3% Much worse than peer group: -21.4% - ROA
-
-46.3% Worse than peer group: -36.1% - Asset turnover
-
7.6% Even with peer group: 6.0% - FCF margin
-
-562.4% Much better than peer group: -2,662.8% - FCF yield
-178.0% - Efficiency ratio
764.2% - Net sales per employee
-
€138.04K - Net income per employee
-
-€836.42K